Personalis at Immuno Week Europe: July 6-9, 2021


Maik Pruess

Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.

Wednesday, JUL  7 | 10:50 AM BST

Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach

  • Predicting patient response to immunotherapies requires a robust approach to tumor immunogenomics.
  • By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a broad view of the tumor and the immune- related components of the tumor microenvironment from a single sample preparation.
  • Combination of ImmunoID NeXT and our exome-wide liquid biopsy assay, NeXT Liquid Biopsy, allows for increased exploration of critical areas of tumor biology.

Connect with us at Immuno Week Europe 2021